{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:03:28Z","timestamp":1780027408117,"version":"3.53.1"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ustekinumab and vedolizumab are used off\u2010label for pediatric inflammatory bowel disease (PIBD). Real\u2010world data are needed to determine their positioning and safety. To assess the (1) 6\u2010month and 1\u2010year clinical outcome on ustekinumab and vedolizumab in PIBD based on Pediatric Ulcerative Colitis Activity Index, short Pediatric Crohn's Disease Activity Index, and calprotectin, and (2) secondary measures including safety and endoscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective chart review of children and young adults with inflammatory bowel disease (IBD) treated at a pediatric academic hospital and two outpatient practices. Patients &lt;21 years old with IBD were included if they received ustekinumab or vedolizumab between January 2015 and June 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred eight patients were included. Patients with ulcerative colitis or IBD\u2010unclassified had significantly higher 1\u2010year steroid\u2010free clinical remission with vedolizumab compared to ustekinumab (61% vs. 32%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) with a similar but nonsignificant trend at 6 months (59% vs. 38%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12). Most patients with Crohn's disease receiving vedolizumab and ustekinumab achieved 6\u2010month clinical remission (63% vs. 68%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.70) and 1\u2010year steroid\u2010free remission (64% vs. 67%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.90). Most patients receiving vedolizumab or ustekinumab achieved calprotectin &lt;250\u2009\u03bcg\/g at 6 months (73% vs. 61%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.20) and 1 year (60% vs. 63%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.90), respectively. A greater proportion of biologic\u2010na\u00efve patients received vedolizumab, whereas most patients on ustekinumab were biologic\u2010exposed. Adverse events occurred in 6.6% and 10% of patients on vedolizumab and ustekinumab, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ustekinumab and vedolizumab are safe and effective in achieving clinical remission at 6 months and 1 year in PIBD. Comparative efficacy clinical trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70198","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:21:02Z","timestamp":1755750062000},"page":"1197-1207","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010world efficacy of ustekinumab and vedolizumab in pediatric and young adult patients with inflammatory bowel disease"],"prefix":"10.1002","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5475-886X","authenticated-orcid":false,"given":"Diane","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology and Nutrition Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lee","sequence":"additional","affiliation":[{"name":"Quantitative Sciences Unit Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Kotzen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology and Nutrition Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bensen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology and Nutrition Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9605-3734","authenticated-orcid":false,"given":"Alka","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Hepatology and Nutrition Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.282"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04857.x"},{"key":"e_1_2_7_4_1","unstructured":"AbbVie Inc. HUMIRA\u00ae (Adalimumab) Injection for Subcutaneous Use. Prescribing Information. Accessed November 27 2022.https:\/\/www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"e_1_2_7_5_1","unstructured":"Janssen Biotech Inc. REMICADE (Infliximab) for Injection for Intravenous Use. Prescribing Information. Accessed November 27 2022.https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.03.006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac036"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab089"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17092"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002362"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16388"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15128"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy206"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04063-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03229-x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-018-0868-x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx082"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2019.09164"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000865"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003758"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05255-y"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00307-7"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000276"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16246"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12169"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12252"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab039"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4980-0"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)01878-4"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_2_7_33_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002556"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14751"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002833"},{"key":"e_1_2_7_37_1","unstructured":"Ustekinumab (Lexi\u2010Drugs)\u2014UpToDate\u00ae LexidrugTM. Accessed June 17 2024.https:\/\/online-lexi-com.proxy.libraries.rutgers.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/1650039?cesid=8ORrkfrsMuU&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dustekinumab%26t%3Dname%26acs%3Dfalse%26acq%3Dustekinumab#arsc"},{"key":"e_1_2_7_38_1","unstructured":"Vedolizumab (Lexi\u2010Drugs)\u2014UpToDate\u00ae LexidrugTM. Accessed June 17 2024.https:\/\/online-lexi-com.proxy.libraries.rutgers.edu\/lco\/action\/doc\/retrieve\/docid\/patch_f\/5161002?cesid=6Zvz45VyAbf&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dvedolizumab%26t%3Dname%26acs%3Dfalse%26acq%3Dvedolizumab#arsc"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:35:10Z","timestamp":1780025710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/jpn3.70198"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70198","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}